Cargando…

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

BACKGROUND: Oral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PIONEER 2 cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malkin, Samuel J. P., Carvalho, Davide, Costa, Catarina, Conde, Vasco, Hunt, Barnaby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845275/ https://www.ncbi.nlm.nih.gov/pubmed/35164855 http://dx.doi.org/10.1186/s13098-022-00801-4

Ejemplares similares

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
por: Viljoen, Adie, et al.
Publicado: (2018)

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
por: Malkin, Samuel J. P., et al.
Publicado: (2019)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy
por: Ren, Hongye, et al.
Publicado: (2023)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
por: Capehorn, Matthew, et al.
Publicado: (2021)

Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
por: Hunt, Barnaby, et al.
Publicado: (2019)

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11
por: Evans, Marc, et al.
Publicado: (2022)

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
por: Eliasson, Björn, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
por: Ramos, Mafalda, et al.
Publicado: (2020)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
por: Iacobellis, Gianluca, et al.
Publicado: (2020)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
por: Ruan, Zhen, et al.
Publicado: (2022)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)
por: Matza, Louis S., et al.
Publicado: (2019)

Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
por: Reppo, Ingrid, et al.
Publicado: (2023)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial
por: Ishii, Hitoshi, et al.
Publicado: (2021)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial
por: Prakash, Prashanth S, et al.
Publicado: (2022)

Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model
por: Park, Hye Jung, et al.
Publicado: (2019)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects
por: Snitker, Søren, et al.
Publicado: (2021)

Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study
por: Barrett, Annabel, et al.
Publicado: (2023)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting
por: Drummond, Russell, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_807bh1g44m8m6kgrbuonurh3gi